Bottom line
LYFAX vs LOGSX: the short answer
LYFAX (AlphaCentric Life Sciences and Healthcare Fund) and LOGSX (Live Oak Health Sciences Fund) are both mutual funds.
But LYFAX is far broader, holding 62 positions to 28 for LOGSX, so beyond the top names it adds exposure LOGSX doesn't have.
LOGSX is cheaper at 1.04% vs 1.66% — a difference of $62 a year per $10,000 invested.
Over five years, LOGSX returned +8.1% a year vs +4.1% for LYFAX.
LYFAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
LYFAX vs LOGSX side by side
| LYFAX | LOGSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Mutual | Oak Associates |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.66% | 1.04% |
| Annual cost per $10k | $166 | $104 |
| 10-yr cost on $10k (prospectus) | $3,039 | $1,271 |
| Max front load | 5.75% | — |
| 12b-1 fee | 0.25% | — |
| 1-yr return | +20.6% | +19.6% |
| 5-yr return (annualized) | +4.1% | +8.1% |
| 10-yr return (annualized) | — | +7.3% |
| Best quarter | +27.5% | +13.4% |
| Worst quarter | −11.9% | −13.1% |
| Net assets (fund) | $46.6M | $56.1M |
| Number of holdings | 62 | 28 |
| Portfolio turnover | 107% | 24% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | LYFAX | LOGSX | Difference |
|---|---|---|---|
| 2025 | +27.9% | +19.6% | +8.3% |
| 2024 | −0.4% | +0.2% | −0.6% |
| 2023 | +6.9% | +1.2% | +5.7% |
| 2022 | −1.1% | +3.7% | −4.8% |
| 2021 | −3.6% | +17.5% | −21.1% |
| 2020 | +54.4% | +6.0% | +48.4% |
Source: Fund prospectus bar charts
Holdings overlap
5 of LYFAX's top 25 holdings also appear in LOGSX's top 25.
| Holding | LYFAX | LOGSX |
|---|---|---|
| Gilead Sciences Inc | 5.53% | 3.50% |
| Vertex Pharmaceuticals Inc | 5.33% | 3.26% |
| Incyte Corp | 3.51% | 3.30% |
| Jazz Pharmaceuticals Plc | 1.87% | 5.77% |
| Amgen Inc | 1.83% | 4.86% |
Source: SEC Form N-PORT
LYFAX top 10
- Gilead Sciences Inc — 5.53%
- Vertex Pharmaceuticals Inc — 5.33%
- Astrazeneca Plc — 4.63%
- First American Funds Inc — 4.26%
- Roivant Sciences Ltd — 3.67%
- Argenx Se — 3.59%
- Neurocrine Biosciences Inc — 3.51%
- Incyte Corp — 3.51%
- Axsome Therapeutics Inc — 3.43%
- Apogee Therapeutics Inc — 3.28%
LOGSX top 10
- N/a — 6.91%
- Cardinal Health Inc — 5.86%
- Jazz Pharmaceuticals Plc — 5.77%
- United Therapeutics Corp — 5.11%
- Exelixis Inc — 4.95%
- Amgen Inc — 4.86%
- Lantheus Holdings Inc — 4.68%
- Novartis Ag — 4.67%
- Mckesson Corp — 4.53%
- Cencora Inc — 4.46%
FAQ
What is the difference between LYFAX and LOGSX?
Which is cheaper, LYFAX or LOGSX?
Should I own both LYFAX and LOGSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.